Harmony Biosciences Holdings, I (HRMY) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $31.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX; Concentration risk — Supplier: Bioprojet.
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy EDS and cataplexy in adults and pediatric patients in the US, with pipeline in idiopathic hypersomnia, rare epilepsy, and other neurological diseases. Revenue is derived almost... Read more
Hold if already holding. Not a fresh buy at $31.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX; Concentration risk — Supplier: Bioprojet. Chart setup: Death cross but MACD improving, RSI 68. Exceptional business at discount. Quality + value alignment. | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Score 6.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductWAKIX10-K Item 1A: 'our business has been substantially dependent on WAKIX and our financial results have been significantly influenced by sales of WAKIX'
- HIGHSupplierBioprojet10-K Item 1A: 'We rely on our license agreements with Bioprojet to provide rights to the core intellectual property relating to pitolisant, and any termination or loss of significant rights under the agreement would adversely affect'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMCFO Sandip Kapadia stepped down Apr 14, 2026 to pursue other career opportunities. Glenn Reicin appointed CFO effective Apr 14, 2026 as same-day successor. Separation Agreement entered into.SEC filing →
- 2026-04-02Item 5.02LOWPeter Anastasiou named Senior EVP and COO effective Apr 2, 2026; simultaneously resigned as Class III Board member, not due to any disagreement with the Company or Board.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $31.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: WAKIX; Concentration risk — Supplier: Bioprojet. Chart setup: Death cross but MACD improving, RSI 68. Exceptional business at discount. Quality + value alignment. | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Target $37.41 (+20.3%), stop $28.98 (−7.3%), A.R:R 1.6:1. Score 6.9/10, moderate confidence.
Take-profit target: $37.41 (+20.1% upside). Target $37.41 (+20.3%), stop $28.98 (−7.3%), A.R:R 1.6:1. Stop-loss: $28.98.
Concentration risk — Product: WAKIX; Concentration risk — Supplier: Bioprojet; Earnings in 7 days (event risk).
Harmony Biosciences Holdings, I trades at a P/E of 11.5 (forward 5.4). TrendMatrix value score: 9.0/10. Verdict: Hold.
17 analysts cover HRMY with a consensus score of 3.8/5. Average price target: $43.
What does Harmony Biosciences Holdings, I do?Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy EDS and cataplexy in...
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy EDS and cataplexy in adults and pediatric patients in the US, with pipeline in idiopathic hypersomnia, rare epilepsy, and other neurological diseases. Revenue is derived almost entirely from WAKIX prescriptions, the only non-scheduled FDA-approved narcolepsy treatment.